Methods for determining the prognosis for cancer patients using tucan
CA 2446825 A1 · Owner: The Burnham Institute · Inventors: Reed, John C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient and (b) comparing , the level of TUCAN in the sample to a reference level of TUCAN wherein a low , level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient and (b) classifying , the patient as belonging to either a first or second group of patients wherein the first group of patients having low levels of TUCAN is classified as having an …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 7, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.